Isoproterenol Hydrochloride
Phase 3Small molecule
Isoproterenol Hydrochloride is one of 6 small molecule programs targeting Sex Differences. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Sex Differences
#DrugCompanyPhaseTrials
1Inderal
Mylan Pharmaceuticals IncApproved
Bronitin Mist
LLongeveron Inc.
Approved
Phenylephrine Hydrochloride
BayerPhase 3
Phentolamine Mesylate
NNovalar Pharmaceuticals, Inc.
Phase 3
Isoproterenol Hydrochloride
UUniversity of Alberta
Phase 3
Nipride
EExela Pharma Sciences, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Isoproterenol Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Alberta